Flaws in a tumor's genetic mending kit drive treatment response to immunotherapy

(Johns Hopkins Medicine) In an expanded, three-year clinical trial of 86 patients with colorectal and 11 other kinds of cancer that have so-called 'mismatch repair' genetic defects, scientists at Johns Hopkins Medicine and its Bloomberg~Kimmel Institute for Cancer Immunotherapy have found that half of the patients respond to an immunotherapy drug called pembrolizumab (Keytruda).
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news